Impact of ISO 10993-1:2025 on Global Approvals | CRO India

Impact of ISO 10993-1:2025 on Global Approvals

Introduction

Global approval of medical devices depends heavily on how well manufacturers demonstrate biocompatibility and patient safety. Regulatory authorities such as the US FDA, EU Notified Bodies and other international agencies rely on the ISO 10993 series to evaluate biological risks.

With the release of ISO 10993-1:2025, expectations around biocompatibility have become clearer, stricter and more science-driven.

For manufacturers targeting multiple markets, understanding the impact of ISO 10993-1:2025 on global approvals is critical. This updated standard influences submission quality, review timelines and approval outcomes.

In this blog, Accuprec Research Labs Pvt. Ltd. explains how ISO 10993-1:2025 affects regulatory approvals worldwide and what manufacturers should do to stay compliant.

Why Biocompatibility Plays a Key Role in Global Approvals

Biocompatibility evaluation ensures that a medical device does not cause harmful biological reactions when used as intended.

Regulatory authorities view biocompatibility as a core safety requirement, especially for devices that contact the body for prolonged or permanent durations.

Incomplete or poorly justified biocompatibility data often leads to:

• Regulatory questions and deficiency letters
• Delays in approval timelines
• Requests for additional testing
• Increased development costs

ISO 10993-1:2025 aims to reduce these issues by setting clearer expectations for biological evaluation.

What Changed in ISO 10993-1:2025 That Affects Approvals

ISO 10993-1:2025 introduces several updates that directly impact how regulators assess submissions:

• Stronger integration with risk management
• Greater emphasis on chemical characterization
• Reduced dependence on animal testing
• Clear expectations for scientific justification
• Better use of existing and clinical data

These changes are aligned with modern regulatory thinking and global harmonization efforts.

Impact on US FDA Approvals

FDA’s Approach to Biocompatibility

The US FDA has long supported a risk-based and science-driven approach to biocompatibility.

In recent years, the FDA has increasingly emphasized:

• Chemical characterization
• Toxicological risk assessment
• Use of non-animal testing methods

ISO 10993-1:2025 aligns well with these expectations.

How ISO 10993-1:2025 Helps FDA Submissions

When manufacturers follow ISO 10993-1:2025, FDA submissions typically show:

• Clear linkage between biocompatibility and risk management
• Strong scientific rationale for test selection or exclusion
• Reduced unnecessary animal testing
• Better structured BEP and BER documents

As a result, FDA reviewers can more easily assess safety, often reducing review questions and delays.

Impact on EU MDR Approvals

EU MDR and Biocompatibility

Under the EU Medical Device Regulation (MDR), Notified Bodies apply stricter scrutiny to clinical and biological safety data.

Biocompatibility deficiencies are a common cause of nonconformities during MDR assessments.

Alignment of ISO 10993-1:2025 with EU MDR

ISO 10993-1:2025 supports MDR compliance by:

• Reinforcing risk management principles
• Supporting clinical evaluation with biological evidence
• Encouraging the use of existing clinical and post-market data
• Improving documentation quality

Manufacturers using the 2025 version are better positioned to meet MDR expectations and avoid repeated review cycles.

Impact on Other Global Markets

International Regulatory Authorities

Many countries, including Canada, Australia, Japan and emerging markets, rely on ISO standards for regulatory decisions.

ISO 10993-1:2025 provides a globally accepted framework that supports harmonized submissions.

Benefits for Multi-Market Approvals

Using ISO 10993-1:2025 allows manufacturers to:

• Prepare a single robust biocompatibility strategy
• Reduce market-specific rework
• Improve consistency across regulatory submissions

This approach saves time and resources while improving approval success rates.

Improved Quality of Regulatory Submissions

Better Biological Evaluation Plans (BEP)

ISO 10993-1:2025 clearly defines expectations for BEPs.

A strong BEP helps regulators understand:

• The evaluation strategy
• Device-specific risks
• Justification for testing decisions

Clear BEPs reduce misunderstandings during review.

Stronger Biological Evaluation Reports (BER)

BERs prepared under ISO 10993-1:2025 are more structured and defensible.

They include:

• Traceability to risk management
• Evaluation of chemical and toxicological data
• Clear conclusions on biological safety

This improves reviewer confidence and approval outcomes.

Reduced Regulatory Questions and Delays

One of the biggest benefits of ISO 10993-1:2025 is the reduction of regulatory questions.

Submissions aligned with the updated standard are less likely to receive:

• Requests for additional testing
• Clarification questions
• Justification challenges

This leads to smoother reviews and faster approvals.

Transition Challenges for Manufacturers

While ISO 10993-1:2025 offers many benefits, manufacturers may face challenges during transition, such as:

• Updating legacy biocompatibility files
• Revising BEP and BER documentation
• Strengthening chemical characterization capabilities
• Training teams on new expectations

Early planning and expert support can significantly reduce these challenges.

Best Practices for Global Approval Success

To maximize approval success under ISO 10993-1:2025, manufacturers should:

• Integrate biocompatibility with risk management early
• Perform chemical characterization as a foundation
• Use toxicological risk assessment to justify decisions
• Leverage existing clinical and post-market data
• Maintain clear, well-documented BEP and BER

These practices align with global regulatory expectations.

How Accuprec Research Labs Supports Global Approvals

Accuprec Research Labs Pvt. Ltd. supports medical device manufacturers seeking global approvals by providing:

• ISO 10993-1:2025–aligned biocompatibility strategies
• Chemical characterization and extractables/leachables studies
• Toxicological risk assessment (ISO 10993-17)
• BEP and BER preparation for FDA and EU MDR
• Regulatory support for global submissions

Our approach focuses on scientific rigor, regulatory compliance and efficient approvals.

Conclusion

ISO 10993-1:2025 has a significant impact on global medical device approvals.

By promoting a risk-based, science-driven approach to biocompatibility, the standard helps regulators better assess patient safety while reducing unnecessary testing.

Manufacturers who align early with ISO 10993-1:2025 are more likely to achieve smoother reviews, fewer regulatory questions and faster approvals across global markets.

With the right expertise and planning, compliance with the updated standard becomes a strong advantage.